IFNG and neoplasm: At the same time, effector T cells, revitalized following anti-PD-1 immunotherapy, reinforce tumor vascular normalization by enhancing IFN-γ and other pathways, which extends the therapeutic window of anlotinib’s vascular normalization properties (24).